These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1424 related articles for article (PubMed ID: 18286529)

  • 21. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.
    Strathdee G; Davies BR; Vass JK; Siddiqui N; Brown R
    Carcinogenesis; 2004 May; 25(5):693-701. PubMed ID: 14729589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer.
    Kikuchi R; Tsuda H; Kozaki K; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
    Cancer Res; 2008 Jul; 68(13):5067-75. PubMed ID: 18593905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors.
    Czekierdowski A; Czekierdowska S; Danilos J; Czuba B; Sodowski K; Sodowska H; Szymanski M; Kotarski J
    J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():53-65. PubMed ID: 18955754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imprinting of PEG3, the human homologue of a mouse gene involved in nurturing behavior.
    Murphy SK; Wylie AA; Jirtle RL
    Genomics; 2001 Jan; 71(1):110-7. PubMed ID: 11161803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines.
    Imura M; Yamashita S; Cai LY; Furuta J; Wakabayashi M; Yasugi T; Ushijima T
    Cancer Lett; 2006 Sep; 241(2):213-20. PubMed ID: 16303245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Expression, loss of heterozygosity, and methylation of GNAT1 gene in nasopharyngeal carcinoma].
    Yi HM; Ren CP; Peng D; Zhou L; Li H; Yao KT
    Ai Zheng; 2007 Jan; 26(1):9-14. PubMed ID: 17222360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic regulation of ARHI in breast and ovarian cancer cells.
    Yu Y; Fujii S; Yuan J; Luo RZ; Wang L; Bao J; Kadota M; Oshimura M; Dent SR; Issa JP; Bast RC
    Ann N Y Acad Sci; 2003 Mar; 983():268-77. PubMed ID: 12724231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
    Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer.
    Soejima H; Nakagawachi T; Zhao W; Higashimoto K; Urano T; Matsukura S; Kitajima Y; Takeuchi M; Nakayama M; Oshimura M; Miyazaki K; Joh K; Mukai T
    Oncogene; 2004 May; 23(25):4380-8. PubMed ID: 15007390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers.
    Gloss BS; Patterson KI; Barton CA; Gonzalez M; Scurry JP; Hacker NF; Sutherland RL; O'Brien PM; Clark SJ
    Cancer Lett; 2012 May; 318(1):76-85. PubMed ID: 22155104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
    Kikuchi R; Tsuda H; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
    Cancer Res; 2007 Aug; 67(15):7095-105. PubMed ID: 17671176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells.
    Nishimoto A; Yu Y; Lu Z; Mao X; Ren Z; Watowich SS; Mills GB; Liao WS; Chen X; Bast RC; Luo RZ
    Cancer Res; 2005 Aug; 65(15):6701-10. PubMed ID: 16061651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer.
    Kang S; Dong SM; Park NH
    Gynecol Oncol; 2010 Jul; 118(1):58-63. PubMed ID: 20421128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
    Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
    Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of PRTFDC1 silencing and aberrant promoter methylation of GPR150, ITGA8 and HOXD11 in ovarian cancers.
    Cai LY; Abe M; Izumi S; Imura M; Yasugi T; Ushijima T
    Life Sci; 2007 Mar; 80(16):1458-65. PubMed ID: 17303177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells.
    Ahluwalia A; Hurteau JA; Bigsby RM; Nephew KP
    Gynecol Oncol; 2001 Aug; 82(2):299-304. PubMed ID: 11531283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer.
    Feng W; Lu Z; Luo RZ; Zhang X; Seto E; Liao WS; Yu Y
    Int J Cancer; 2007 Apr; 120(8):1664-8. PubMed ID: 17230502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
    Lu KH; Patterson AP; Wang L; Marquez RT; Atkinson EN; Baggerly KA; Ramoth LR; Rosen DG; Liu J; Hellstrom I; Smith D; Hartmann L; Fishman D; Berchuck A; Schmandt R; Whitaker R; Gershenson DM; Mills GB; Bast RC
    Clin Cancer Res; 2004 May; 10(10):3291-300. PubMed ID: 15161682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
    Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
    J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.
    Cvetkovic D; Pisarcik D; Lee C; Hamilton TC; Abdollahi A
    Gynecol Oncol; 2004 Dec; 95(3):449-55. PubMed ID: 15581945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 72.